Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · IEX Real-Time Price · USD
13.81
+0.56 (4.23%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Teva Pharmaceutical Employees
Teva Pharmaceutical Industries had 37,851 employees on December 31, 2023. The number of employees increased by 1,025 or 2.78% compared to the previous year.
Employees
37,851
Change (1Y)
1,025
Growth (1Y)
2.78%
Revenue / Employee
$418,642
Profits / Employee
-$14,768
Market Cap
15.48B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 37,851 | 1,025 | 2.78% |
Dec 31, 2022 | 36,826 | -711 | -1.89% |
Dec 31, 2021 | 37,537 | -2,679 | -6.66% |
Dec 31, 2020 | 40,216 | 177 | 0.44% |
Dec 31, 2019 | 40,039 | -2,496 | -5.87% |
Dec 31, 2018 | 42,535 | -9,257 | -17.87% |
Dec 31, 2017 | 51,792 | -5,168 | -9.07% |
Dec 31, 2016 | 56,960 | 14,072 | 32.81% |
Dec 31, 2015 | 42,888 | -121 | -0.28% |
Dec 31, 2014 | 43,009 | -1,936 | -4.31% |
Dec 31, 2013 | 44,945 | -1,003 | -2.18% |
Dec 31, 2012 | 45,948 | 194 | 0.42% |
Dec 31, 2011 | 45,754 | 6,094 | 15.37% |
Dec 31, 2010 | 39,660 | 4,571 | 13.03% |
Dec 31, 2009 | 35,089 | -3,218 | -8.40% |
Dec 31, 2008 | 38,307 | 10,395 | 37.24% |
Dec 31, 2007 | 27,912 | 1,242 | 4.66% |
Dec 31, 2006 | 26,670 | 11,972 | 81.45% |
Dec 31, 2005 | 14,698 | 885 | 6.41% |
Dec 31, 2004 | 13,813 | 2,853 | 26.03% |
Dec 31, 2003 | 10,960 | 1,383 | 14.44% |
Dec 31, 2002 | 9,577 | 591 | 6.58% |
Dec 31, 2001 | 8,986 | 361 | 4.19% |
Dec 31, 2000 | 8,625 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Walgreens Boots Alliance | 331,000 |
Laboratory Corporation of America Holdings | 67,000 |
Quest Diagnostics | 48,000 |
Viatris | 38,000 |
The Cooper Companies | 15,000 |
BeiGene | 10,600 |
Hologic | 6,990 |
BioMarin Pharmaceutical | 3,401 |
TEVA News
- 11 days ago - Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets - Business Wire
- 16 days ago - Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China - Business Wire
- 18 days ago - Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024 - Business Wire
- 21 days ago - New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024 - Business Wire
- 23 days ago - Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate - Business Wire
- 26 days ago - Teva, Viatris win new chance to challenge J&J schizophrenia drug patent - Reuters
- 4 weeks ago - Teva UK and Closed Loop Medicine Announce Strategic Partnership to Advance Development of Personalised Medicines - Business Wire
- 2 months ago - Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China - Business Wire